Klöckner Pentaplast expands pharma capacity in China

Comments Email

Klöckner Pentaplast’s pharmaceutical & medical device films division (kp Pharma) has started up a recent expansion at its production facility in Suzhou, China.

The company announced 9 April that its converting capabilities has increased in China through the installation of a new slitting line at its Chinese site.

This, said the German packaging firm, will reduce lead times and increase flexibility for all material grades supplied into the Chinese market.

The new, qualified slitting centre has a closed clean room environment, meeting China's rigorous requirements of ISO 15378.

Furthermore, the site has a fully operational micro-biological lab for quality control purposes.

“We are seeing substantial growth in all product segments in Asia. New CFDA regulations in China are increasing the focus on the quality and performance of the packaging materials used, as well as increased demand for barrier performance to protect the sensitivity of new drugs,” said Tracey Peacock, president, Pharmaceutical & Medical Device Films at kp.

The new capacity will also support the Asian market as it continues to experience double-digit growth.

“We have been quietly adding to our capabilities in other parts of the world and now we will accelerate the actions to address the growing Asian market place,” Tracey Peacock went on to say.

Asia, she said, provides “exciting opportunities” for kp as regulation continues to increase with many EMEA and US standards being adopted.


Select from the list below to subscribe to customized Plastics News Europe e-mail news alerts. Check the options you wish to receive.